Compare BARK & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BARK | CMPS |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.2M | 646.2M |
| IPO Year | N/A | 2020 |
| Metric | BARK | CMPS |
|---|---|---|
| Price | $0.60 | $6.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.50 | ★ $16.43 |
| AVG Volume (30 Days) | 827.2K | ★ 1.3M |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $451,690,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $2.25 |
| 52 Week High | $2.32 | $7.15 |
| Indicator | BARK | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 61.86 |
| Support Level | $0.58 | $6.56 |
| Resistance Level | $0.66 | $7.15 |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 34.93 | 71.50 |
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.